Companies in #Extracorporeal Immunomodulation
Found 1 company operating in this sector.
SeaStar Medical is a commercial-stage medical-device company developing the Selective Cytopheretic Device (SCD), a cell-directed extracorporeal immunomodulator that targets and neutralizes overactivated neutrophils and monocytes in hyperinflammatory conditions. The SCD received FDA Breakthrough Device designation and is being evaluated in clinical and commercial programs for adult Acute Kidney Injury (AKI) and pediatric Hepatorenal Syndrome. The company completed a 1-for-10 reverse stock split in January 2026 to maintain Nasdaq minimum bid-price compliance.